A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase.
CPK elevation
daptomycin
myalgia
statin
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
10
04
2019
accepted:
28
10
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
15
11
2019
Statut:
epublish
Résumé
Daptomycin has been associated with increased creatine phosphokinase (CPK) due to muscle injury leading to myalgias and muscle weakness. Statins have been proven to cause the same effects and it is recommended to discontinue the use of statins while on daptomycin. Evidence regarding this drug interaction is mixed. This study evaluated the risk of CPK elevation in concomitant use of daptomycin and statins compared to daptomycin alone. This is a multisite retrospective case-control study of patients who received daptomycin therapy with monitoring of CPK. Rates of CPK elevations were compared in patients receiving daptomycin with a statin versus daptomycin alone. To estimate the association between CPK elevation and daptomycin therapy controlling for other risk factors, logistic regression was used to analyze data. Statistical significance was determined at ɑ of 0.05. A total of 3658 patients were included in the study, with 2787 on daptomycin therapy alone and 871 with concurrent statin use. The incidence of CPK elevation was 90 events (3.2%) in the daptomycin group and 26 events (3.0%) in the concurrent statin group. Patients who received daptomycin therapy in addition to statins had no statistically significant difference from patients on daptomycin alone (hazard ratio, 1.05; Concomitant use of daptomycin and statin did not show an increase risk of CPK elevation. Clinicians may consider concomitant use of daptomycin and statin therapy with weekly CPK monitoring.
Identifiants
pubmed: 31723571
doi: 10.1093/ofid/ofz444
pii: ofz444
pmc: PMC6837837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz444Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Heart. 2002 Sep;88(3):229-33
pubmed: 12181210
Drug Metabol Drug Interact. 2013;28(1):49-58
pubmed: 23314530
Ann Pharmacother. 2014 Mar;48(3):320-7
pubmed: 24321853
JAMA. 2007 Jan 10;297(2):177-86
pubmed: 17213401
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1771-4
pubmed: 22160888
Ann Intern Med. 2004 Jun 1;140(11):857-66
pubmed: 15172899
Arch Intern Med. 2004 Oct 25;164(19):2162-8
pubmed: 15505131
Clin Infect Dis. 2018 Oct 15;67(9):1356-1363
pubmed: 29668884
Stroke. 2009 Aug;40(8):2887-92
pubmed: 19520985
Eur Heart J. 2015 May 1;36(17):1012-22
pubmed: 25694464
J Antimicrob Chemother. 2000 Oct;46(4):523-6
pubmed: 11020247
Clin Infect Dis. 2010 Jun 15;50(12):1568-74
pubmed: 20462352
In Vitro Cell Dev Biol Anim. 2010 Jul;46(7):613-8
pubmed: 20383664
Expert Opin Drug Saf. 2012 May;11(3):439-44
pubmed: 22416996
Muscle Nerve. 2010 Sep;42(3):385-93
pubmed: 20544940
Infect Dis Ther. 2014 Dec;3(2):225-33
pubmed: 25245515
J Pharmacogenomics Pharmacoproteomics. 2014 Apr 23;5(2):null
pubmed: 25221728
Cleve Clin J Med. 2016 Jan;83(1):37-42
pubmed: 26760521
Neurology. 2007 Aug 28;69(9):904-10
pubmed: 17724294
Antimicrob Agents Chemother. 2014 Oct;58(10):5726-31
pubmed: 25022580
Clin Pharmacol Ther. 2012 Jul;92(1):112-7
pubmed: 22617227